Cover Image

A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA)

Show other versions (1)

Advanced esophageal squamous cell cancer (ESCC) is frequently diagnosed in elderly patients. The impact of 2nd line chemotherapy is poorly defined. Recent data demonstrated effectiveness of checkpoint inhibitors in different squamous cell carcinomas. Therefore, we assess combined nivolumab/ipilimuma...

Full description

Saved in:
Bibliographic Details
Main Authors: Meindl-Beinker, Nadja M. (Author) , Betge, Johannes (Author) , Gutting, Tobias (Author) , Burgermeister, Elke (Author) , Belle, Sebastian (Author) , Zhan, Tianzuo (Author) , Schulte, Nadine (Author) , Ebert, Matthias (Author) , Härtel, Nicolai (Author)
Format: Article (Journal)
Language:English
Published: 14 March 2019
In: BMC cancer
Year: 2019, Volume: 19
ISSN:1471-2407
DOI:10.1186/s12885-019-5446-2
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s12885-019-5446-2
Get full text
Author Notes:Nadja M. Meindl-Beinker, Johannes Betge, Tobias Gutting, Elke Burgermeister, Sebastian Belle, Tianzuo Zhan, Nadine Schulte, Martin Maenz, Matthias P. Ebert and Nicolai Haertel
Description
Summary:Advanced esophageal squamous cell cancer (ESCC) is frequently diagnosed in elderly patients. The impact of 2nd line chemotherapy is poorly defined. Recent data demonstrated effectiveness of checkpoint inhibitors in different squamous cell carcinomas. Therefore, we assess combined nivolumab/ipilimumab as 2nd line therapy in elderly ESCC patients.
Item Description:Gesehen am 10.04.2019
Physical Description:Online Resource
ISSN:1471-2407
DOI:10.1186/s12885-019-5446-2

Similar Items